Skip to main content
. 2018 Aug 3;9(60):31572–31589. doi: 10.18632/oncotarget.25803

Figure 7. The palbociclib-PD0325901 combination reduces tumor burden and improves progression-free survival in a genetically-engineered mouse model of KRAS-mutant NSCLC.

Figure 7

A. Waterfall plot indicating the percent change in tumor burden of mice treated with vehicle, palbociclib alone, PD0325901 alone or the palbociclib-PD0325901 combination for up to 18 weeks. B. Western blot analysis of CDK and cyclin expression and ERK and AKT activation in tumor lysates isolated at the study endpoint for each treatment group. C. Western blot analysis of the activity of the mTOR pathway in tumor lysates isolated at the study endpoint for each treatment group. D. Kaplan-Meier survival plots for experimental groups treated with PDO325901 alone or in combination with palbociclib. Significance was assessed using the Log rank test for trend. E. Percent body weight change for mice in the 4 treatment groups over the treatment duration.